Form 4: 10x Genomics CEO Sells Shares for Tax Obligations
Insider Transaction Report
10x Genomics CEO Serge Saxonov sold 9,632 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.
Summary
- Serge Saxonov, CEO and Director of 10x Genomics, Inc. (TXG), sold 9,632 shares of Class A Common Stock.
- The transaction occurred on February 23, 2026, at a price of $18.5764 per share.
- The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
- Following the transaction, Saxonov directly beneficially owns 1,061,924 shares of Class A Common Stock.
- Additionally, Saxonov indirectly beneficially owns 27 shares through the Andromeda Trust, 213,250 shares through the Y/S Descendants' Trust, and 58,000 shares through the Y/S Pot Trust, for which he serves as trustee.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. The transaction is a routine, non-discretionary sale to cover tax obligations, which does not reflect a change in the insider's investment sentiment or the company's operational performance.
Industry Context
StockSavvy.ai notes that insider sales to cover tax withholding obligations upon RSU vesting are a common and routine occurrence across all industries, particularly in high-growth technology and biotech sectors like genomics, and typically do not signal a change in management's long-term outlook for the company.
Related Party Transactions
- Serge Saxonov indirectly beneficially owns shares held by the Andromeda Trust, Y/S Descendants' Trust, and Y/S Pot Trust, for which he serves as trustee.
Stakeholder Impact
- Minimal impact on shareholders as this is a routine, non-discretionary transaction for tax purposes and does not indicate a change in the executive's confidence in the company.
- No direct impact on employees, customers, suppliers, or creditors from this specific transaction.
Key Dates
| Date | Description |
|---|---|
| 02/23/2026 | Date of transaction for the sale of Class A Common Stock. |
| 02/24/2026 | Date of execution for the Power of Attorney document. |
| 02/25/2026 | Date the Form 4 was signed by the Attorney-in-Fact. |
Keywords
10x Genomics, TXG, Serge Saxonov, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, CEO, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.